Drug class profile · refreshed daily from federal data

alpha-1 Adrenergic Agonist

2 molecules in this class, $56521 combined CY2024 Part D spend across 1K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the alpha-1 Adrenergic Agonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $56521combined across class
Total Rx claims: 1K1K unique beneficiaries
Generic mfrs (active): 16across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Phenylephrine

Brand: Biorphen · 1K Part D claims (CY24) · 1K beneficiaries · First FDA approval: 2012-12-18

16 generic mfrs

Low NADAC$9.20

→

Avg plan cost$9.20

Part D spend $56521 1× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Phenylephrine Hydrochloride Injection, Solution

— Part D claims (CY24) · First FDA approval: 2025-07-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.